Therefore, in the United States, a phase 1 clinical trial (NCT05040217) is currently underway, investigating the administration of brain-derived neurotrophic factor (BDNF) into the brain using AAV2-BDNF vectors in patients with early AD or mild cognitive impairment (MCI). Here, BDNF is linked to Cognitive impairment.